Last reviewed · How we verify
Moxifloxacin Tablets, USP
At a glance
| Generic name | Moxifloxacin Tablets, USP |
|---|---|
| Sponsor | Impax Laboratories, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects (PHASE1)
- To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moxifloxacin Tablets, USP CI brief — competitive landscape report
- Moxifloxacin Tablets, USP updates RSS · CI watch RSS
- Impax Laboratories, LLC portfolio CI